CSL Behring's Privigen has obtained marketing authorization from the European Commission for use in chronic inflammatory demyelinating polyneuropathy (CIDP). Privigen is an immune globulin intravenous [human], 10% liquid, developed for ...
Tags: CSL Behring Privigen, European Marketing Authorization
CSL Behring has submitted a Variation Application to the European Medicines Agency (EMA) for the use of Privigen (immune globulin intravenous [human], 10% liquid for intravenous administration) in Chronic Inflammatory Demyelinating ...
Tags: CSL Behring, Variation Application, Privigen, CIDP